{"id":"NCT00847626","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension","officialTitle":"A Phase 3, Double-Blind, Randomized, Factorial, Efficacy and Safety Study of TAK 491 Plus Chlorthalidone Fixed-Dose Combination in Participants With Moderate to Severe Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2010-05","completion":"2010-07","firstPosted":"2009-02-19","resultsPosted":"2012-02-07","lastUpdate":"2012-02-07"},"enrollment":1711,"design":{"allocation":"RANDOMIZED","model":"FACTORIAL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Azilsartan medoxomil and chlorthalidone","otherNames":["TAK-491CLD"]},{"type":"DRUG","name":"Azilsartan medoxomil and chlorthalidone","otherNames":["TAK-491CLD"]},{"type":"DRUG","name":"Azilsartan medoxomil and chlorthalidone","otherNames":["TAK-491CLD"]},{"type":"DRUG","name":"Azilsartan medoxomil and chlorthalidone","otherNames":["TAK-491CLD"]},{"type":"DRUG","name":"Azilsartan medoxomil and chlorthalidone","otherNames":["TAK-491CLD"]},{"type":"DRUG","name":"Azilsartan medoxomil and chlorthalidone","otherNames":["TAK-491CLD"]},{"type":"DRUG","name":"Chlorthalidone","otherNames":[]},{"type":"DRUG","name":"Chlorthalidone","otherNames":[]},{"type":"DRUG","name":"Azilsartan medoxomil","otherNames":["TAK-491CLD"]},{"type":"DRUG","name":"Azilsartan medoxomil","otherNames":["TAK-491CLD"]},{"type":"DRUG","name":"Azilsartan medoxomil","otherNames":["TAK-491CLD"]}],"arms":[{"label":"Azilsartan medoxomil 20 mg/chlorthalidone 12.5 mg QD","type":"EXPERIMENTAL"},{"label":"Azilsartan medoxomil 20 mg/chlorthalidone 25 mg QD","type":"EXPERIMENTAL"},{"label":"Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg QD","type":"EXPERIMENTAL"},{"label":"Azilsartan medoxomil 40 mg/chlorthalidone 25 mg QD","type":"EXPERIMENTAL"},{"label":"Azilsartan medoxomil 80 mg/chlorthalidone 12.5 mg QD","type":"EXPERIMENTAL"},{"label":"Azilsartan medoxomil 80 mg/chlorthalidone 25 mg QD","type":"EXPERIMENTAL"},{"label":"Chlorthalidone 12.5 mg QD","type":"ACTIVE_COMPARATOR"},{"label":"Chlorthalidone 25 mg QD","type":"ACTIVE_COMPARATOR"},{"label":"Azilsartan medoxomil 20 mg QD","type":"EXPERIMENTAL"},{"label":"Azilsartan medoxomil 40 mg QD","type":"EXPERIMENTAL"},{"label":"Azilsartan medoxomil 80 mg QD","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe hypertension.","primaryOutcome":{"measure":"Change From Baseline to Week 8 in Trough, Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)","timeFrame":"Baseline and Week 8.","effectByArm":[{"arm":"Azilsartan Medoxomil 40 mg or 80 mg/Chlorthalidone 25 mg QD","deltaMin":-28.9,"sd":0.89},{"arm":"Chlorthalidone 25 mg QD","deltaMin":-15.9,"sd":1.16},{"arm":"Azilsartan Medoxomil 80 mg QD","deltaMin":-15.1,"sd":1.19}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":99,"countries":["United States","Chile","Mexico","Peru","Russia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":156},"commonTop":["Blood creatinine increased","Dizziness","Headache","Blood creatine phosphokinase increased","Blood uric acid increased"]}}